Knockout of CD45 was achieved by CRISPR-Cas9 genome editing using LentiArray™ Lentiviral sgRNA (Product # A32042, Assay ID CRIPSR664208_LV) and LentiArray Cas9 Lentivirus (Product # A32064). Western blot analysis of CD45 was performed by loading 30 µg of THP-1 Cas9 (Lane 1) andTHP-1 CD45 KO (Lane 2) membrane enriched extracts. The samples were electrophoresed using NuPAGE™ 3 to 8%, Tris-Acetate, 1.0 mm, Mini Protein Gel (Product # EA0375PK2). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with a CD45 Monoclonal Antibody (Bra55) (Product # MA5-12795, 1:100 dilution) and Goat anti-Mouse IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A28177, 1:2,500 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using SuperSignal™ West Dura Extended Duration Substrate (Product # 34076). Loss of signal upon CRISPR mediated knockout (KO) using the LentiArray™ CRISPR product line confirms that antibody is specific to CD45. An uncharacterised band was observed at ~60 kDa in THP-1 Cas9 sample.